Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)

Completed · Phase 2

Conditions studied: Amyotrophic Lateral Sclerosis

In brief

This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with ALS.

Key facts

Study ID

NCT04569435

Run by

Annexon, Inc.

People needed

17

Starts

2021-01-15

Expected to finish

2024-04-23

Last updated by the study team

2025-01-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Annexon Investigational Site 04 — Phoenix, Arizona, United States
• Annexon Investigational Site 01 — Orange, California, United States
• Annexon Investigational Site 02 — Gainesville, Florida, United States
• Annexon Investigational Site 03 — Tampa, Florida, United States
• Annexon Investigational Site 10 — Edmonton, Alberta, Canada
• Annexon Investigational Site 09 — Toronto, Ontario, Canada
• Annexon Investigational Site 07 — Montreal, Quebec, Canada
• Annexon Investigational Site 08 — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.